Skye Bioscience Investors Face Jan. 16 Lead-Plaintiff Deadline in Lawsuit Over Nimacimab Claims

Shareholders are not represented unless they retain counsel at this stage.

Overview

Multiple investor firms report that a securities class action has been filed against Skye Bioscience (NASDAQ: SKYE).
The case challenges statements made during November 4, 2024 to October 3, 2025 concerning the company and its lead drug candidate, nimacimab.
Complaints allege nimacimab was less effective than portrayed, which allegedly overstated its clinical, regulatory, and commercial prospects.
Motions to be appointed lead plaintiff are due by January 16, 2026, though serving as lead plaintiff is not required to share in any potential recovery.
Rosen Law Firm, The Gross Law Firm, and Levi & Korsinsky are soliciting affected investors and highlight contingency-fee representation with no upfront costs.